Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker
disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and
whether early MSUS measures/MBDA can predict response to therapy.